The spread of mammographic screening programmes around the world, including in developing countries, has substantially contributed to the diagnosis of small non-palpable lesions, which has increased the detection rate of DCIS (ductal carcinoma in situ). DCIS is heterogeneous in several ways, such as its clinical presentation, morphology and genomic profile. Excellent outcomes have been reported...

Background The incidence of detected ductal carcinoma in situ (DCIS) continues to increase and now accounts for 14% all breast cancer, 20%-25% screen-detected cases. Treatment trends DCIS are important order inform the ongoing debate about possible overdiagnosis overtreatment, but have not been investigated over a decade Australia New Zealand. Against this background, we aimed describe temporal...

Background: Considering highly selected patients with ductal carcinoma in situ (DCIS), active surveillance is a valid alternative to surgery. Our study aimed show the reliability of post-biopsy complete lesion removal, documented by mammogram, as additional criterion select these patients. Methods: A total 2173 vacuum-assisted breast biopsies (VABBs) DCIS were reviewed. Surgery was performed al...

Wouldn't it be easier if we lived in a binary world? Everything would be either black or white, yes or no, 1 or 0. And biopsy results would be either normal or cancer. Unfortunately, in the world of cancer, our efforts to detect the disease early have made this a fantasy. We are increasingly faced with the reality of a big gray zone — a broad spectrum of pathologic fi ndings between normal tiss...

Ductal carcinoma in situ (DCIS) of the breast is becoming one of the most important diseases diagnosed in preventive medicine screening. The current age-adjusted incidence rate of DCIS is 32.5 per 100,000 women. For women 50–64 years of age, the incidence is approximately 88 per 100,000. Currently, for every 4 diagnoses of invasive breast cancer, there is 1 diagnosis of DCIS. Risk of DCIS is ra...

Adjuvant antiestrogen (AE) therapy has been proposed for all women with ductal carcinoma in situ (DCIS). However, many cases of DCIS are of the high-grade, estrogen receptor (ER)-negative subtype that are unlikely to respond to AE treatment. Hormonal agents work by increasing apoptosis and/or decreasing cell proliferation; therefore, we studied the effect of a pure AE on levels of apoptosis and...

PURPOSE The purpose of this study is to determine relative accuracy of mammography (MMG), ultrasonography (US), and magnetic resonance imaging (MRI) in patients with ductal carcinoma in situ (DCIS) as compared with pathology finding. METHOD AND MATERIALS Institutional review board approval was obtained with waiver of informed consent. Between January 2001 and December 2008, 91 women with 97 les...

BACKGROUND Endocrine therapy initiation after ductal carcinoma in situ (DCIS) is highly variable and largely unexplained. National guidelines recommend considering tamoxifen for women with estrogen receptor-positive (ER+) DCIS or who undergo excision alone. We evaluated endocrine therapy use after DCIS over a 15-year period in an integrated health care setting to identify factors related to ini...

BACKGROUND Ductal carcinoma in situ (DCIS) has a generally favorable overall prognosis, with a systemic recurrence rate of approximately 1%, a local recurrence rate after mastectomy of 1%, and a local recurrence rate after breast-conserving treatment of less than 10%. Preliminary studies have suggested that women with DCIS may overestimate their risk of disease recurrence. Few data exist regard...

BACKGROUND Breast carcinoma in situ (CIS) is classified into ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). DCIS is treated with surgical excision while LCIS can be clinically followed with or without hormonal treatment. Thus, it is critical to distinguish DCIS from LCIS. Immunohistochemical (IHC) staining for E-cadherin is routinely used to differentiate DCIS from LCIS i...